MYLK3

Summary

MYLK3 (myosin light chain kinase 3, HGNC:29826) is a protein-coding gene on chromosome 16q11.2, encoding Myosin light chain kinase 3 (Q32MK0). Kinase that phosphorylates MYL2 in vitro.

Phosphorylation of cardiac myosin heavy chains (see MYH7B, MIM 609928) and light chains (see MYL2, MIM 160781) by a kinase, such as MYLK3, potentiates the force and rate of cross-bridge recruitment in cardiac myocytes (Chan et al., 2008 [PubMed 18202317]).

Source: NCBI Gene 91807 — RefSeq curated summary.

At a glance

• Gene–disease (curated): dilated cardiomyopathy (Moderate, ClinGen)
• Clinical variants (ClinVar): 1,054 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes — 24 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_182493

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29826
Approved symbol	MYLK3
Name	myosin light chain kinase 3
Location	16q11.2
Locus type	gene with protein product
Status	Approved
Aliases	caMLCK, MLCK
Ensembl gene	ENSG00000140795
Ensembl biotype	protein_coding
OMIM	612147
Entrez	91807

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000394809, ENST00000536476, ENST00000562104, ENST00000564731, ENST00000565182, ENST00000569810, ENST00000569844, ENST00000874186, ENST00000874187, ENST00000971334

RefSeq mRNA: 2 — MANE Select: NM_182493 NM_001308301, NM_182493

CCDS: CCDS10723, CCDS76861

Canonical transcript exons

ENST00000394809 — 13 exons

Exon	Start	End
ENSE00000945062	46747717	46748344
ENSE00000945064	46737711	46738143
ENSE00000945070	46721123	46721193
ENSE00000945071	46712648	46712776
ENSE00000945076	46727236	46727377
ENSE00002603072	46702282	46707763
ENSE00003542772	46740057	46740147
ENSE00003574018	46709539	46709671
ENSE00003606376	46730593	46730698
ENSE00003606473	46732208	46732668
ENSE00003619656	46710637	46710789
ENSE00003630562	46729024	46729133
ENSE00003672514	46729594	46729687

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 98.13.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.3151 / max 334.2785, expressed in 114 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
157220	0.5650	65
157210	0.5597	44
157218	0.0627	25
157217	0.0383	17
207864	0.0342	13
157219	0.0332	21
157209	0.0114	3
157216	0.0106	9

Top tissues by expression

268 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	98.13	gold quality
myocardium	UBERON:0002349	97.63	gold quality
heart right ventricle	UBERON:0002080	97.45	gold quality
left ventricle myocardium	UBERON:0006566	97.07	gold quality
cardiac atrium	UBERON:0002081	95.61	gold quality
right atrium auricular region	UBERON:0006631	95.22	gold quality
cardiac ventricle	UBERON:0002082	94.18	gold quality
heart left ventricle	UBERON:0002084	94.08	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	93.96	gold quality
body of tongue	UBERON:0011876	93.42	gold quality
apex of heart	UBERON:0002098	92.99	gold quality
biceps brachii	UBERON:0001507	92.25	gold quality
diaphragm	UBERON:0001103	91.94	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.30	gold quality
triceps brachii	UBERON:0001509	90.41	gold quality
heart	UBERON:0000948	90.00	gold quality
vena cava	UBERON:0004087	89.87	gold quality
vastus lateralis	UBERON:0001379	89.44	gold quality
skeletal muscle tissue	UBERON:0001134	88.42	gold quality
buccal mucosa cell	CL:0002336	88.40	gold quality
quadriceps femoris	UBERON:0001377	88.36	gold quality
muscle tissue	UBERON:0002385	87.30	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.11	gold quality
deltoid	UBERON:0001476	84.99	silver quality
renal glomerulus	UBERON:0000074	84.75	gold quality
gluteal muscle	UBERON:0002000	83.52	silver quality
muscle organ	UBERON:0001630	83.44	gold quality
metanephric glomerulus	UBERON:0004736	83.17	gold quality
tibialis anterior	UBERON:0001385	82.62	silver quality
muscle of leg	UBERON:0001383	81.23	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.65
E-HCAD-5	no	226.97

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NKX2-5

miRNA regulators (miRDB)

167 targeting MYLK3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-548AA	99.96	70.64	3753

Literature-anchored findings (GeneRIF, showing 6)

• Integrated cDNA expression analysis of failing human myocardia uncovered a novel protein kinase, cardiac-specific myosin light chain kinase (cardiac-MLCK), which acts on MLC2v. (PMID:17885681)
• data indicate that the IL-1beta-induced increase in MLCK protein expression and Caco-2 TJ permeability was mediated by an increase in MLCK expression and activity and by an NF-kappaB-dependent increase in MLCK gene transcription (PMID:18390750)
• These findings suggest that hepatitis B virus X protein disrupts stress fiber formation and triggers apoptosis via an MLCK and a PTEN-dependent pathway. (PMID:23591626)
• Biochemical and physiological regulation of cardiac myocyte contraction by cardiac-specific myosin light chain kinase. (PMID:23863751)
• This study demonstrates that cyclic stretch disrupts tight junctions and adherens junctions by a JNK2, c-Src, and MLCK-dependent mechanism. (PMID:24722904)
• Study identified MYLK3 mutations associated with familial dilated cardiomyopathy. In vitro experiments and immunohistochemistry suggested that the MYLK3 mutations identified in this study result in markedly reduced levels of protein expression and myosin light chain 2 phosphorylation. (PMID:29235529)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mylk3	ENSDARG00000076348
mus_musculus	Mylk3	ENSMUSG00000031698
rattus_norvegicus	Mylk3	ENSRNOG00000017546

Paralogs (22): CAMKK1 (ENSG00000004660), CAMK1G (ENSG00000008118), CAMK2B (ENSG00000058404), CAMK2A (ENSG00000070808), MYLK2 (ENSG00000101306), CAMKK2 (ENSG00000110931), STK11 (ENSG00000118046), STK33 (ENSG00000130413), PNCK (ENSG00000130822), DCLK1 (ENSG00000133083), CAMK1 (ENSG00000134072), CAMK2D (ENSG00000145349), MYLK4 (ENSG00000145949), PSKH2 (ENSG00000147613), CAMK2G (ENSG00000148660), PHKG2 (ENSG00000156873), PSKH1 (ENSG00000159792), DCLK3 (ENSG00000163673), CAMKV (ENSG00000164076), PHKG1 (ENSG00000164776), DCLK2 (ENSG00000170390), CAMK1D (ENSG00000183049)

Protein

Protein identifiers

Myosin light chain kinase 3 — Q32MK0 (reviewed: Q32MK0)

Alternative names: Cardiac-MyBP-C-associated Ca/CaM kinase

All UniProt accessions (1): Q32MK0

UniProt curated annotations — full annotation on UniProt →

Function. Kinase that phosphorylates MYL2 in vitro. Promotes sarcomere formation in cardiomyocytes and increases cardiomyocyte contractility.

Subcellular location. Cytoplasm.

Tissue specificity. Restricted to heart.

Post-translational modifications. Phosphorylated on serine residues.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q32MK0-3	1	yes
Q32MK0-4	2

RefSeq proteins (2): NP_001295230, NP_872299* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[myosin light chain] + ATP = O-phospho-L-seryl-[myosin light chain] + ADP + H(+) (RHEA:22004)
• L-threonyl-[myosin light chain] + ATP = O-phospho-L-threonyl-[myosin light chain] + ADP + H(+) (RHEA:53900)

UniProt features (21 total): modified residue 4, sequence variant 3, region of interest 3, compositionally biased region 3, binding site 2, sequence conflict 2, chain 1, domain 1, splice variant 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q32MK0-F1	63.26	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 636 (proton acceptor)

Ligand- & substrate-binding residues (2): 544; 521–529

Post-translational modifications (4): 152, 355, 401, 408

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 132 (showing top): GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_RESPONSE_TO_PEPTIDE, GOBP_POSITIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_CARDIAC_MYOFIBRIL_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_SARCOMERE_ORGANIZATION, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, TGCTGAY_UNKNOWN

GO Biological Process (9): signal transduction (GO:0007165), sarcomere organization (GO:0045214), sarcomerogenesis (GO:0048769), cardiac myofibril assembly (GO:0055003), positive regulation of sarcomere organization (GO:0060298), cellular response to interleukin-1 (GO:0071347), positive regulation of tight junction disassembly (GO:1905075), positive regulation of membrane permeability (GO:1905710), protein phosphorylation (GO:0006468)

GO Molecular Function (9): calcium/calmodulin-dependent protein kinase activity (GO:0004683), myosin light chain kinase activity (GO:0004687), ATP binding (GO:0005524), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), actin cytoskeleton (GO:0015629)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
myofibril assembly	3
actomyosin structure organization	2
protein serine/threonine kinase activity	2
cellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cardiac muscle cell development	1
sarcomere organization	1
positive regulation of striated muscle cell differentiation	1
positive regulation of cytoskeleton organization	1
regulation of sarcomere organization	1
positive regulation of supramolecular fiber organization	1
response to interleukin-1	1
cellular response to cytokine stimulus	1
positive regulation of cellular component organization	1
tight junction disassembly	1
regulation of tight junction disassembly	1
regulation of membrane permeability	1
phosphorylation	1
protein modification process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
protein kinase activity	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
cytoskeleton	1

Protein interactions and networks

STRING

1533 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYLK3	CALML3	P27482	964
MYLK3	CALML5	Q9NZT1	964
MYLK3	CALML6	Q8TD86	962
MYLK3	CALML4	Q96GE6	962
MYLK3	CALM1	P02593	928
MYLK3	MYL7	Q01449	825
MYLK3	MYL2	P10916	791
MYLK3	MYH7B	A7E2Y1	760
MYLK3	PPP1R12A	O14974	727
MYLK3	MYL12B	O14950	657
MYLK3	RHOA	P06749	640
MYLK3	PPP1R14A	Q96A00	609
MYLK3	ACTC1	P04270	599
MYLK3	MYL9	P24844	586
MYLK3	PAK1	Q13153	456

IntAct

14 interactions, top by confidence:

A	B	Type	Score
MAPK14	RPS6KA5	psi-mi:“MI:0914”(association)	0.660
MAPK12	MAPK13	psi-mi:“MI:0914”(association)	0.640
MYLK3	YWHAE	psi-mi:“MI:0915”(physical association)	0.400
SFN	MYLK3	psi-mi:“MI:0915”(physical association)	0.400
HSP90AB1	MYLK3	psi-mi:“MI:0915”(physical association)	0.400
ALB	CNOT1	psi-mi:“MI:0914”(association)	0.350
MAPK14	PRKY	psi-mi:“MI:0914”(association)	0.350
MYLK3		psi-mi:“MI:0914”(association)	0.350
MYLK3	OBSL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (17): MYLK3 (Affinity Capture-MS), MYLK3 (Affinity Capture-MS), MYLK3 (Affinity Capture-MS), MYLK3 (Affinity Capture-MS), CALM3 (Affinity Capture-MS), OBSL1 (Affinity Capture-MS), PCDHB11 (Affinity Capture-MS), PCDHB5 (Affinity Capture-MS), OBSL1 (Affinity Capture-MS), MYLK3 (Affinity Capture-MS), CALM3 (Affinity Capture-MS), MYLK3 (Affinity Capture-MS), RBM17 (Cross-Linking-MS (XL-MS)), MYLK3 (Affinity Capture-RNA), MYLK3 (Dosage Lethality)

ESM2 similar proteins: A4IFM7, A8C984, B6D5P1, B6D5P6, E9PT87, O08815, O54988, O55092, O70551, O88831, P00519, P00520, P00521, P07313, P0C865, P13234, P20689, P42684, P46087, Q13164, Q14028, Q16566, Q2KI23, Q32MK0, Q3SYS4, Q3UH66, Q3UIZ8, Q3ULB5, Q4JIM5, Q4KMM3, Q4V8B0, Q5R8Z4, Q5RDG7, Q5TGJ6, Q63553, Q6AYH9, Q6PDI6, Q80XI3, Q8BHL3, Q8BWQ5

Diamond homologs: A0A509AFG4, A0A5K1K8H0, A2AAJ9, A2ZVI7, A4IFM7, A8C984, A8WXF6, B9FKW9, C0HKC8, C0HKC9, E9PT87, O02827, O43293, O44997, O54784, O62305, O70150, O75147, O80673, O88764, O94768, P07313, P08414, P11801, P13234, P15735, P18653, P20689, P29294, P31325, P34101, P43292, P53355, P53681, Q00168, Q00771, Q0KHT7, Q0V7M1, Q10KY3, Q14012

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MYLK3	“up-regulates activity”	MEF2C	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 11 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
intracellular signal transduction	5	19.1×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

1054 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	657
Likely benign	341
Benign	21

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2419098	NM_182493.3(MYLK3):c.1915-1G>T	Likely pathogenic

SpliceAI

2278 predictions. Top by Δscore:

Variant	Effect	Δscore
16:46712644:TCACA:T	donor_loss	1.0000
16:46712645:CA:C	donor_loss	1.0000
16:46712646:A:AC	donor_gain	1.0000
16:46712647:C:CC	donor_gain	1.0000
16:46712647:CAG:C	donor_gain	1.0000
16:46712647:CAGCA:C	donor_gain	1.0000
16:46727231:CCCA:C	donor_loss	1.0000
16:46727232:CCA:C	donor_loss	1.0000
16:46727233:CA:C	donor_loss	1.0000
16:46727234:ACC:A	donor_loss	1.0000
16:46727235:C:A	donor_loss	1.0000
16:46729020:TCACT:T	donor_loss	1.0000
16:46729021:CA:C	donor_loss	1.0000
16:46729022:A:AC	donor_gain	1.0000
16:46729022:ACT:A	donor_loss	1.0000
16:46729023:C:CA	donor_gain	1.0000
16:46729023:C:CT	donor_loss	1.0000
16:46729023:CT:C	donor_gain	1.0000
16:46729023:CTA:C	donor_gain	1.0000
16:46729023:CTACT:C	donor_gain	1.0000
16:46729028:C:CA	donor_gain	1.0000
16:46729145:C:CT	acceptor_gain	1.0000
16:46729145:C:T	acceptor_gain	1.0000
16:46729146:A:T	acceptor_gain	1.0000
16:46740145:ATTC:A	acceptor_loss	1.0000
16:46740146:TT:T	acceptor_gain	1.0000
16:46740148:C:CC	acceptor_gain	1.0000
16:46740148:CTA:C	acceptor_loss	1.0000
16:46709541:T:TA	donor_gain	0.9900
16:46711401:C:CT	acceptor_gain	0.9900

AlphaMissense

5352 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:46712676:A:G	W696R	1.000
16:46712676:A:T	W696R	1.000
16:46712728:G:C	F678L	1.000
16:46712728:G:T	F678L	1.000
16:46712730:A:G	F678L	1.000
16:46721141:T:A	D656V	1.000
16:46727246:A:G	L635P	1.000
16:46709634:A:G	W769R	0.999
16:46709634:A:T	W769R	0.999
16:46709665:T:A	R758S	0.999
16:46709665:T:G	R758S	0.999
16:46709666:C:G	R758T	0.999
16:46712667:C:G	G699R	0.999
16:46712667:C:T	G699R	0.999
16:46712671:A:C	S697R	0.999
16:46712671:A:T	S697R	0.999
16:46712673:T:G	S697R	0.999
16:46712674:C:A	W696C	0.999
16:46712674:C:G	W696C	0.999
16:46712682:C:A	D694Y	0.999
16:46712682:C:G	D694H	0.999
16:46712696:A:T	V689D	0.999
16:46712711:A:T	V684D	0.999
16:46712729:A:G	F678S	0.999
16:46712741:C:T	G674D	0.999
16:46721129:G:T	A660D	0.999
16:46721140:G:C	D656E	0.999
16:46721140:G:T	D656E	0.999
16:46721141:T:C	D656G	0.999
16:46721141:T:G	D656A	0.999

dbSNP variants (sampled 300 via entrez): RS1000020905 (16:46754710 C>A,T), RS1000041279 (16:46720036 C>A,G,T), RS1000071844 (16:46702168 T>C), RS1000072529 (16:46720449 C>T), RS1000077140 (16:46762495 G>A), RS1000147805 (16:46739550 C>T), RS1000184620 (16:46752682 T>C), RS1000221747 (16:46737417 C>A,T), RS1000234971 (16:46719824 C>T), RS1000248810 (16:46764587 A>C,T), RS1000259215 (16:46743790 G>A,T), RS1000280371 (16:46743310 A>G), RS1000309875 (16:46726948 C>T), RS1000339893 (16:46713724 C>T), RS1000448378 (16:46752095 G>A)

Disease associations

OMIM: gene MIM:612147 | disease phenotypes: MIM:614203, MIM:115200

GenCC curated gene-disease

Disease	Classification	Inheritance
dilated cardiomyopathy	Moderate	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
dilated cardiomyopathy	Moderate	AD

Mondo (3): Parkinson disease 17 (MONDO:0013625), dilated cardiomyopathy (MONDO:0005021), familial dilated cardiomyopathy (MONDO:0016333)

Orphanet (3): Hereditary late-onset Parkinson disease (Orphanet:411602), Dilated cardiomyopathy (Orphanet:217604), Familial dilated cardiomyopathy (Orphanet:217607)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001644	Dilated cardiomyopathy

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
C536231	familial dilated cardiomyopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4627 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

24 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 224,246 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1289926	AXITINIB	4	15,732
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL576982	QUIZARTINIB	4	4,432
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL1614713	CC-401	2	389
CHEMBL1721885	SU-014813	2	363
CHEMBL2386889	SCH-900776	2	740
CHEMBL3218578	BGT-226 FREE BASE	2	2,878
CHEMBL495727	AT-9283	2	1,376
CHEMBL564829	MILCICLIB	2	821
CHEMBL572878	TOZASERTIB	2	2,998
CHEMBL1090479	GSK-1070916	1	177
CHEMBL1908397	KW-2449	1	622
CHEMBL2041933	AZD-7762	1	1,240
CHEMBL296468	BMS-387032	1
CHEMBL3128043	PF-03758309	1
CHEMBL3545328	XL-019	1
CHEMBL4289017	PF-03814735	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Myosin Light Chain Kinase (MLCK) family

Binding affinities (BindingDB)

6 measured of 8 human assays (8 total across all organisms); most potent 6 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
BMS-387072	KD	1800 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

46 potent at pChembl≥5 of 47 total, top 45 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.70	Kd	2	nM	DOVITINIB
8.37	Kd	4.3	nM	KW-2449
7.92	Kd	12	nM	LESTAURTINIB
7.82	Kd	15	nM	TOZASERTIB
7.70	Kd	20	nM	SU-014813
7.64	Kd	23	nM	SUNITINIB
7.51	Kd	31	nM	CHEMBL3990456
7.38	Kd	42	nM	SU-014813
7.38	Kd	42	nM	CHEMBL1908395
7.02	Kd	95	nM	LESTAURTINIB
7.01	Kd	98	nM	K-252A
7.01	Kd	98	nM	XL-019
6.98	Kd	104	nM	GSK-1070916
6.96	Kd	109	nM	PF-03814735
6.96	Kd	110	nM	NINTEDANIB
6.93	IC50	118	nM	STAUROSPORINE
6.89	Kd	129	nM	AT-9283
6.89	IC50	129	nM	STAUROSPORINE
6.85	Kd	140	nM	CHEMBL386051
6.85	Kd	140	nM	STAUROSPORINE
6.84	Kd	146	nM	CHEMBL4465866
6.73	IC50	188	nM	STAUROSPORINE
6.72	Kd	189	nM	SCH-900776
6.54	Kd	284.9	nM	CHEMBL5653589
6.49	ED50	327.4	nM	CHEMBL5653589
6.46	Kd	349	nM	PF-03758309
6.46	Kd	350	nM	MILCICLIB
6.44	Kd	360	nM	CHEMBL1241674
6.40	Kd	400	nM	CHEMBL379218
6.39	Kd	410	nM	QUIZARTINIB
6.32	Kd	483	nM	CC-401
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.96	Kd	1105	nM	BGT-226 FREE BASE
5.77	Kd	1700	nM	BMS-387032
5.77	Kd	1700	nM	AXITINIB
5.64	Kd	2300	nM	MIDOSTAURIN
5.53	Kd	2939	nM	NMS-1286937
5.52	Kd	3000	nM	FORETINIB
5.44	Kd	3647	nM	AZD-7762
5.41	Kd	3904	nM	AXITINIB
5.25	Kd	5600	nM	QUIZARTINIB
5.02	Kd	9600	nM	SORAFENIB
5.01	Kd	9700	nM	FEDRATINIB

PubChem BioAssay actives

42 with measured affinity, of 392 total; 34 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	624738: Binding constant for MLCK kinase domain	kd	0.0020	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624738: Binding constant for MLCK kinase domain	kd	0.0043	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	624738: Binding constant for MLCK kinase domain	kd	0.0120	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0150	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0200	uM
Sunitinib	624738: Binding constant for MLCK kinase domain	kd	0.0230	uM
2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-6-yl]acetamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0310	uM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide;hydrochloride	624738: Binding constant for MLCK kinase domain	kd	0.0420	uM
methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0980	uM
N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0980	uM
3-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethylpyrazol-3-yl]phenyl]-1,1-dimethylurea	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1040	uM
N-[2-[4-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-11-yl]-2-oxoethyl]acetamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1090	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624738: Binding constant for MLCK kinase domain	kd	0.1100	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	2198335: Inhibition of human MYLK3 using KKRPQRRYSNVF as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by radiometric Hot-SpotSM Kinase assay	ic50	0.1180	uM
1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1290	uM
6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one	624738: Binding constant for MLCK kinase domain	kd	0.1400	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526132: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged MYLK3 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.1460	uM
6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1890	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148811: Binding affinity to human MYLK3 incubated for 45 mins by Kinobead based pull down assay	kd	0.2849	uM
N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-d]pyrazole-5-carboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.3490	uM
N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,5-h]quinazoline-3-carboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.3500	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	624738: Binding constant for MLCK kinase domain	kd	0.3600	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	624738: Binding constant for MLCK kinase domain	kd	0.4000	uM
Quizartinib	624738: Binding constant for MLCK kinase domain	kd	0.4100	uM
3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.4830	uM
8-(6-methoxy-3-pyridinyl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.1050	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	624738: Binding constant for MLCK kinase domain	kd	1.7000	uM
Axitinib	624738: Binding constant for MLCK kinase domain	kd	1.7000	uM
Midostaurin	624738: Binding constant for MLCK kinase domain	kd	2.3000	uM
8-[2-methoxy-5-(4-methylpiperazin-1-yl)anilino]-1-methyl-4,5-dihydropyrazolo[4,5-h]quinazoline-3-carboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	2.9390	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	624738: Binding constant for MLCK kinase domain	kd	3.0000	uM
3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide	1425082: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.6470	uM
Sorafenib	624738: Binding constant for MLCK kinase domain	kd	9.6000	uM
Fedratinib	624738: Binding constant for MLCK kinase domain	kd	9.7000	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation, increases mutagenesis	4
bisphenol A	decreases methylation, increases expression	3
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Valproic Acid	affects expression, increases expression	2
Aflatoxin B1	increases methylation, decreases expression	2
aristolochic acid I	increases expression	1
Asian ginseng	decreases expression, decreases reaction	1
hydroxyhydroquinone	decreases expression	1
sulforaphane	decreases expression	1
sodium arsenite	affects expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
cyanoginosin LR	increases expression, decreases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Copper	affects cotreatment, decreases expression	1
Diazinon	increases methylation	1
Diethylhexyl Phthalate	decreases expression, decreases reaction	1
Estradiol	increases expression, affects binding	1
Methapyrilene	increases methylation	1
Triclosan	decreases expression	1
Asbestos, Serpentine	decreases methylation	1
Asbestos, Crocidolite	decreases methylation	1
Asbestos, Amosite	decreases methylation	1
Nanotubes, Carbon	decreases expression	1

ChEMBL screening assays

95 unique, capped per target: 95 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1908435	Binding	Binding constant for MLCK kinase domain	Comprehensive analysis of kinase inhibitor selectivity. — Nat Biotechnol

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0IP	Ubigene HeLa MYLK3 KO	Cancer cell line	Female
CVCL_SZ62	HAP1 MYLK3 (-) 1	Cancer cell line	Male
CVCL_SZ63	HAP1 MYLK3 (-) 2	Cancer cell line	Male
CVCL_SZ64	HAP1 MYLK3 (-) 3	Cancer cell line	Male
CVCL_SZ65	HAP1 MYLK3 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy